---
title: "2025 國談第四日上午場開啓：華潤三九、以嶺藥業入場 中藥品種開始談判"
description: "記者從 2025 年國家醫保目錄現場談判與商保創新藥目錄價格協商現場獲悉，2025 國談第四日進程於 8 時左右開始，華潤三九、健民藥業、北京以嶺藥業、衞材、科睿藥業等藥企代表依次進場等待談判。中藥企業代表密集進場，預計中藥品種開始談判。"
type: "news"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/263867464.md"
published_at: "2025-11-02T00:59:20.000Z"
---

# 2025 國談第四日上午場開啓：華潤三九、以嶺藥業入場 中藥品種開始談判

> 記者從 2025 年國家醫保目錄現場談判與商保創新藥目錄價格協商現場獲悉，2025 國談第四日進程於 8 時左右開始，華潤三九、健民藥業、北京以嶺藥業、衞材、科睿藥業等藥企代表依次進場等待談判。中藥企業代表密集進場，預計中藥品種開始談判。

記者從 2025 年國家醫保目錄現場談判與商保創新藥目錄價格協商現場獲悉，2025 國談第四日進程於 8 時左右開始，華潤三九、健民藥業、北京以嶺藥業、衞材、科睿藥業等藥企代表依次進場等待談判。中藥企業代表密集進場，預計中藥品種開始談判。

### Related Stocks

- [002603.CN - 以嶺藥業](https://longbridge.com/zh-HK/quote/002603.CN.md)
- [000999.CN - 華潤三九](https://longbridge.com/zh-HK/quote/000999.CN.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Yiling Pharmaceutical Unit Gets China Nod for Alzheimer's Drug Raw Material | Yiling Pharmaceutical Unit Gets China Nod for Alzheimer's Drug Raw Material | [Link](https://longbridge.com/zh-HK/news/265661137.md) |
| Yiling Pharmaceutical Withdraws Drug Registration Application for Chaihuang Lidan Capsules | Yiling Pharmaceutical Withdraws Drug Registration Application for Chaihuang Lidan Capsules | [Link](https://longbridge.com/zh-HK/news/267815314.md) |
| Forget Regencell Bioscience: This blue chip drug maker is the boring compounder you need | Don't follow general market sentiment when it comes to these two stocks. | [Link](https://longbridge.com/zh-HK/news/277366138.md) |
| China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025 | China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. reported earnings results for the full year ended December 31, | [Link](https://longbridge.com/zh-HK/news/275124956.md) |
| InterRent REIT Publishes MD&A for Year Ended Dec. 31, 2025 | InterRent REIT reported a portfolio occupancy of 96.9% for December 2025, with average monthly rent increasing by 2.8% y | [Link](https://longbridge.com/zh-HK/news/277549019.md) |

---

> **免責聲明**：本文內容僅供參考，不構成任何投資建議。